Historical award
Biogen U.S. Corporation
This record is historical buying context, not open work.
How current is this award history?
Fiscal year 2025: data through (10 days old).
Fiscal year 2026: data through (10 days old).
Official release availability details
Fiscal year 2025: This is the latest release listed by USAspending. A latest release can still omit recent activity.
Availability checked: .
Fiscal year 2026: This is the latest release listed by USAspending. A latest release can still omit recent activity.
Availability checked: .
- Potential award value
- $11,392,063.40
- Total obligated to date
- $0.00
Source date: Nov 9, 2026
Recorded work
BILATERAL MODIFICATION IS ISSUED TO NOTIFY BIOGEN U.S. CORPORATION, THAT THE GOVERNMENT WILL NOT EXERCISE THE 2ND OPTION YEAR FOR RANIBIZUMAB (BYOOVIZ) VIALS. THE CONTRACT WILL EXPIRE ON 12/22/2025 AT THE END OF THE 1ST OPTION YEAR.
Award activity
- Obligations in covered fiscal years
- $0.00
- Transactions in covered fiscal years
- 4
Award value and obligated funds describe different amounts. Review the official record for the full transaction history.
Record identifier
CONT_IDV_36E79724D0002_3600